IMR Press / CEOG / Volume 47 / Issue 5 / DOI: 10.31083/j.ceog.2020.05.5238
Open Access Case Report
A novel effective treatment for menière’s disease - dextroamphetamine sulfate
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, 08103 NJ, United States
2 Cooper institute for reproductive hormonal disorders, p.c. mt. laurel, 08054 NJ, United States
Clin. Exp. Obstet. Gynecol. 2020 , 47(5), 807–809; https://doi.org/10.31083/j.ceog.2020.05.5238
Submitted: 18 April 2019 | Accepted: 10 June 2019 | Published: 15 October 2020
Abstract

Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea. Methods: Dextroamphetamine sulfate was started at 9.4 mg extended release tablets and eventually increased to 18.8 mg (Adzenys®). Results: The symptoms of constant ear fullness and severe tinnitus abated and have not returned for 2 years. In addition, the edema of the fingers and ankles have abated along with an 11 pound weight loss. Conclusions: Menière’s disease can be added to the long list of chronic treatment resistant conditions lumped together under the name of the increased cellular permeability syndrome. This syndrome may or may not be associated with pelvic pain. The common denominator is that these seemingly unrelated conditions affecting many organ systems all respond markedly well to amphetamine therapy. The hypothesis of the efficacy of dextroamphetamine sulfate is that it releases dopamine from sympathetic nerve fibers, which, in turn, diminishes cellular permeability.

Keywords
Menière’s disease
Increased cellular permeability syndrome
Dextroamphetamine sulfate
Dopamine
Dysmenorrhea
Share
Back to top